The statements below are read from Evoq Remedies Limited’s filed results, 3 filed quarters and 8 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed May 31, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY25Mar 2025 | H1 FY26Sep 2025 | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 11.8 | 25.5 | 0.00 | -100.0% |
| 12.4 | 26.5 | 0.49 | -96.0% | |
| Operating profit | -0.61 | -0.96 | -0.49 | n/m |
| OPM % | -5.2% | -3.7% | — | — |
| Other income | 2.40 | 1.06 | 0.19 | -92.2% |
| Interest | 0.00 | 0.00 | 0.00 | — |
| Depreciation | 0.04 | 0.03 | 0.02 | -45.0% |
| Profit before tax | 1.75 | 0.08 | -0.33 | -118.8% |
| Tax % | 2.3% | 31.1% | n/a (loss) | — |
| Net profit | 1.71 | 0.05 | -0.29 | -117.2% |
| EPS (₹) | 0.69 | 0.02 | -0.12 | -117.4% |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
